Sanofi withdrew its cholesterol drug Praluent from the Chinese market due to competition and supply issues. President Trump warned of potential U.S. pharmaceutical tariffs reaching 250%. A PitchBook analysis revealed a decline in Southeast Asian venture capital activity, while Biogen reported growth in Leqembi sales. China’s Minghui Pharmaceutical raised $131 million for drug development.

Sanofi completed the acquisition of Vigil Neuroscience for approximately $470 million to strengthen its neurology pipeline, specifically targeting Alzheimer’s disease with the drug VG-3927. The acquisition, valued at $470 million, is a strategic move to enhance research in neurodegenerative diseases and does not impact Sanofi’s 2025 financial guidance.

Sanofi, a French biopharmaceutical company, has completed the acquisition of U.S.-based Vigil Neuroscience, a clinical-stage biotech firm focused on developing treatments for neurodegenerative diseases. The deal includes the acquisition of Vigil's preclinical pipeline and its lead candidate VG-3927, a TREM2 agonist targeting Alzheimer’s disease, for a total equity value of approximately €405 million, with Sanofi paying €6.91 per share in cash and granting shareholders a contingent value right of €1.73 per share upon the first commercial sale of VG-3927. The acquisition strengthens Sanofi’s neurology pipeline and aligns with its strategic focus on advancing immunology-based therapies for unmet needs in neurodegenerative diseases. Vigil’s second clinical candidate, VGL101, targeting a rare disease, was not included in the transaction. The acquisition does not impact Sanofi’s 2025 financial guidance.

Sanofi completed its acquisition of Vigil Neuroscience, making it a wholly owned subsidiary. The deal involved converting Vigil shares into cash and contingent value rights (CVRs), with shareholder approval. Vigil's stock was delisted from Nasdaq, and the company faces regulatory and clinical trial developments.

Sanofi has purchased an exclusive license for plozasiran from Visirna Therapeutics for $130 million, allowing Sanofi to develop and commercialize the drug in China. The drug targets hypertriglyceridemia and familial chylomicronemia syndrome (FCS), with Visirna having completed a Phase III trial and submitted an NDA to China’s National Medical Products Administration (NMPA). Sanofi will pay $130 million upfront and receive milestone payments, while Arrowhead Pharmaceuticals may receive royalties on sales.